PATENT CLAIM ANALYSIS

Application Number: 15957122
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["514", "009600"]

Abstract:
The invention relates to treatment and prevention of heart failure in a mammal. The invention provides a dosing regimen whereby the therapeutic benefits conferred by administration of peptide comprising an epidermal growth factor-like domain, e.g., a neuregulin such as glial growth factor 2 (GGF2) or a functional fragment thereof, are maintained and/or enhanced, while concomitantly minimizing any potential side effects.

Claim (Index 2):
The method of  claim 1 , wherein the peptide comprising an EGF-like domain is administered to the subject according to an escalating dosing regimen, said method comprising administering said peptide at a first therapeutically effective dose, and subsequently administering a second therapeutically effective dose, wherein the second dose is higher than the first dose.

Metadata:
- Claim Count in Document: 32.0
- Percentile: 91.0
- Lexical Diversity: 1.19298
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13904654', '14928124', '13059206', '15357586', '14844475']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7498370631706918
- 35 USC 102 Novelty (BERT): 0.5571314430483582
- Combined Prediction Score: 0.7305665011584583
- Mean Citation Score: 367.206068
- Max Citation Score: 440.68204
- Similarity Product: 292.3861818325305

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test